Merck Says Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint In Patients With Breast Cancer

Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, announced Thursday positive results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent (adjuvant) treatment after surgery.

KEYNOTE-522 met its dual primary endpoint of event-free survival (EFS) for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC).

Based on an interim analysis conducted by the independent Data Monitoring Committee (DMC), neoadjuvant KEYTRUDA plus chemotherapy followed by adjuvant KEYTRUDA as monotherapy showed a statistically significant and clinically meaningful improvement in EFS compared with neoadjuvant chemotherapy alone.

KEYNOTE-522 had also met its other dual primary endpoint of pathological complete response (pCR) earlier. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies and no new safety signals were identified.

KEYTRUDA Is the first anti-PD-1 therapy to show a statistically significant improvement in EFS as neoadjuvant and adjuvant Therapy for TNBC.

The KEYTRUDA clinical development program for TNBC encompasses several internal studies and external collaborative trials, including the ongoing studies KEYNOTE-242 and KEYNOTE-355. There are about 20 registrational studies ongoing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Spirit Airlines has canceled or delayed hundreds of flights following significant operational challenges. The low-cost carrier blamed weather, staffing shortages, and system outages for the issues that caused thousands of passengers stranded in the airports. General Motors Co. (GM) said its second-quarter results were better than originally expected due to strong pricing and demand, record GM Financial results and improved near-term production from the pull forward of semiconductors from the third quarter. Based on first-half performance and expectations... PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately...
Follow RTT